Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Checkpoint Inhibitor in Addition to Transurethral Resection of Bladder Cancer (TUBRT) and Radiation Therapy in Patients With cT2-4aN0M0 Bladder Cancer: a Mono-centre Clinical Study

NCT05445648 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT05445648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05445648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Checkpoint Inhibitor in Addition to Transurethral Resection of Bladder Cancer (TUBRT) and Radiation Therapy in Patients With cT2-4aN0M0 Bladder Cancer: a Mono-centre Clinical Study
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2023
Completion date
February 28, 2026
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasms